2024 was a big year for weight loss drugs like Ozympic and Wigovi.

More patients are relying on them to manage their weight, treat diabetes, or prevent heart attacks and strokes.

And while they are highly effective, they also come with some concerns.

William Brangham has more on the rising demand for these drugs, which are part of a class of medications known as GLP1.

About one in eight U.S. adults now say they have taken a GLP1.

But amid all the excitement about their efficacy, some experts also say it's important to keep in mind some of the drug's limits, their costs, and to better

understand where they belong in the nation's long fight against obesity.

For a check-in on where this all stands, we are joined now by Dr. Jody Doucher. She's an assistant

professor of medicine at Harvard Medical School and a clinical endocrinologist who specializes in medical weight management.

Dr. Doucher, so nice to have you on the program.

You prescribe these drugs to some of your patients.

From your perspective, what do they do?

How effective are they, especially at helping people lose weight?

Well, first I want to say thank you very much for having

me. It's a pleasure to be on the show. And also, I just want to mention that I don't have any

conflicts of interest. So in terms of how these medications work and how effective they are, a lot of

times what I'll hear is patients using the same words to describe how they work.

So people will tell me that they have reduced cravings, that they think about food less.

A lot, there's been use of this term food noise. So people will tell me that they have a lot

less food noise. So they are thinking about food a lot less. Whereas maybe before

you wake up in the morning and you're thinking about what you're going to have for breakfast,

while you're having breakfast, you're already thinking about what you're going to eat next after

...